Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 4
Abstract
Serum hepatitis B virus (HBV) DNA level is a predictor of the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients. Nevertheless, the distribution of viral load levels in chronic HBV patients in Brazil has yet to be described. This cross-sectional study included 564 participants selected in nine Brazilian cities located in four of the five regions of the country using the database of a medical diagnostics company. Admission criteria included hepatitis B surface antigen seropositivity, availability of HBV viral load samples and age 18 years. Males comprised 64.5% of the study population. Mean age was 43.7 years. Most individuals (62.1%) were seronegative for the hepatitis B e antigen (HBeAg). Median serum ALT level was 34 U/L. In 58.5% of the patients HBV-DNA levels ranged from 300 to 99,999 copies/mL; however, in 21.6% levels were undetectable. Median HBV-DNA level was 2,351 copies/mL. Over 60% of the patients who tested negative for HBeAg and in whom ALT level was less than 1.5 times the upper limit of the normal range had HBV-DNA levels > 2,000 IU/mL, which has been considered a cut-off point for indicating a liver biopsy and/or treatment. In conclusion, HBV-DNA level identified a significant proportion of Brazilian individuals with chronic hepatitis B at risk of disease progression. Furthermore, this tool enables those individuals with high HBV-DNA levels who are susceptible to disease progression to be identified among patients with normal or slightly elevated ALT.
Authors and Affiliations
Marcelo Nita, Nelson Gaburo Jr, Hugo Cheinquer, Gilbert Italien, Evaldo Affonso de Araujo, Patricia Mantilla, Nancy Cure-Bolt, Paulo Lotufo
Keywords
Related Articles
- EP ID EP77889
- DOI -
- Views 148
- Downloads 0
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
Introduction. A large number of patients with chronic hepatitis C have not been cured with interferon-based therapy. Therefore, we evaluated the efficacy of amantadine combined with the standard of care(pegylated interfe...
The good, the bad and the ugly of the new treatments for hepatitis C virus
Elevated circulating levels of IL-21 and IL-22 define a cytokine signature profile in type 2 autoimmune hepatitis patients
Background and aims. Autoimmune hepatitis (AIH) is a chronic inflammatory condition of the liver in which the immunologicalmechanisms involved in tissue destruction and/or repair are still unclear. Different pro-inflamm...
Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence
Hepatitis C virus (HCV) is a small, enveloped RNA virus. The number of HCV-infected individuals worldwide is estimated to be approximately 200 million. The vast majority of HCV infections persist, with up to 80% of all c...
Association of amino acid imbalance with the severity of liver fibrosis and esophageal varices
[b]Background[/b]. The relationships between the metabolic parameters and the endoscopic findings of esophageal varices have been poorly investigated. We investigated the association of the branched-chain amino acids tot...